iSpecimen Stock Scheduled to Reverse Split on Tuesday, April 28th (NASDAQ:ISPC)

iSpecimen Inc. (NASDAQ:ISPC)’s stock is going to reverse split on Tuesday, April 28th. The 1-40 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, April 27th.

iSpecimen Trading Down 19.6%

ISPC stock traded down $0.03 during midday trading on Friday, reaching $0.13. The stock had a trading volume of 27,448,865 shares, compared to its average volume of 63,885,900. The company’s fifty day simple moving average is $0.20 and its 200 day simple moving average is $0.40. The company has a market cap of $3.87 million, a price-to-earnings ratio of -0.06 and a beta of 1.98. iSpecimen has a 52-week low of $0.10 and a 52-week high of $3.18.

iSpecimen (NASDAQ:ISPC) last posted its quarterly earnings results on Wednesday, April 1st. The company reported ($0.74) EPS for the quarter. iSpecimen had a negative return on equity of 496.31% and a negative net margin of 543.37%.The company had revenue of $0.05 million for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of iSpecimen in a report on Tuesday. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Institutional Trading of iSpecimen

A hedge fund recently bought a new stake in iSpecimen stock. Virtu Financial LLC acquired a new position in shares of iSpecimen Inc. (NASDAQ:ISPC) in the third quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 63,257 shares of the company’s stock, valued at approximately $82,000. Virtu Financial LLC owned about 0.65% of iSpecimen at the end of the most recent quarter. 13.62% of the stock is currently owned by hedge funds and other institutional investors.

About iSpecimen

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.